Published in Discov Med on March 01, 2010
Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. J Clin Invest (2016) 2.06
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med (2011) 1.06
T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J (2012) 0.99
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol (2015) 0.96
Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol (2012) 0.95
A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. J Control Release (2013) 0.94
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci (2015) 0.93
Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol (2014) 0.90
NETs: the missing link between cell death and systemic autoimmune diseases? Front Immunol (2013) 0.89
Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol (2013) 0.88
Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc Natl Acad Sci U S A (2013) 0.88
Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res Ther (2012) 0.85
Mitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunity. Oncotarget (2015) 0.84
Small molecules in the treatment of systemic lupus erythematosus. Clin Immunol (2012) 0.83
Allele-specific down-regulation of RPTOR expression induced by retinoids contributes to climate adaptations. PLoS Genet (2010) 0.81
Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions. Clin Exp Immunol (2013) 0.81
Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus. Oxid Med Cell Longev (2016) 0.80
miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4(+) T lymphocytes of patients with relapsing-remitting multiple sclerosis. Immunogenetics (2015) 0.78
A case of lymphangioleiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus. BMC Cancer (2016) 0.76
Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE. Clin Immunol (2011) 0.75
Metabolic Factors that Contribute to Lupus Pathogenesis. Crit Rev Immunol (2016) 0.75
A case of systemic lupus erythematosus with multiple nodules in the bilateral lungs and vertebrae. Eur J Rheumatol (2015) 0.75
Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. J Cell Physiol (2017) 0.75
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
mTOR signaling at a glance. J Cell Sci (2009) 8.66
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity (2009) 6.86
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood (2005) 6.49
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med (2008) 6.07
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A (2008) 5.97
The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44
Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol (2008) 3.43
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 3.22
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (1982) 3.10
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1993) 2.88
Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum (2008) 2.62
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol (2009) 2.39
Translational control of the innate immune response through IRF-7. Nature (2008) 2.30
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol (2005) 2.00
A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet (2008) 1.98
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One (2009) 1.69
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.44
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A (2009) 1.38
Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 1.38
Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum (1994) 1.36
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 1.34
Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol (2010) 2.89
Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum (2002) 2.08
Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 1.76
Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest (2009) 1.75
Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum (2002) 1.62
Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol (2004) 1.54
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol (2009) 1.52
T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol (2003) 1.39
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2012) 1.38
Metabolic control of T cell activation and death in SLE. Autoimmun Rev (2008) 1.28
T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol (2005) 1.27
Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem (2006) 1.16
Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol (2007) 1.08
Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry (2012) 1.08
Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol (2014) 1.03
Pathogenic mechanisms in systemic lupus erythematosus. Autoimmunity (2010) 1.02
Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol (2009) 0.99
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol (2013) 0.99
T lymphocytes from patients with systemic lupus erythematosus are resistant to induction of autophagy. FASEB J (2012) 0.99
Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor γ. J Immunol (2012) 0.96
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol (2008) 0.96
Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum (2008) 0.95
Nitric oxide, mitochondrial hyperpolarization, and T cell activation. Free Radic Biol Med (2007) 0.94
Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol (2005) 0.93
Immunofluorescence microscopy is superior to fluorescent beads for detection of antinuclear antibody reactivity in systemic lupus erythematosus patients. Clin Immunol (2007) 0.93
Adhesion-dependent Skp2 transcription requires selenocysteine tRNA gene transcription-activating factor (STAF). Biochem J (2011) 0.92
Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother (2009) 0.91
Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J (2008) 0.91
ZNF143 mediates basal and tissue-specific expression of human transaldolase. J Biol Chem (2003) 0.91
Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosus. Antioxid Redox Signal (2014) 0.90
Tuberous sclerosis and fulminant lupus in a young woman. J Clin Rheumatol (2013) 0.88
CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J Immunol (2005) 0.87
Detection of lupus anticoagulant and successful anticoagulation in familial Sneddon syndrome. Ann Rheum Dis (2010) 0.87
Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol (2014) 0.87
CCL genes in multiple sclerosis and systemic lupus erythematosus. J Neuroimmunol (2008) 0.86
Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocr Metab Immune Disord Drug Targets (2006) 0.86
Possible pathogenic nature of the recently discovered TT virus: does it play a role in autoimmune rheumatic diseases? Autoimmun Rev (2006) 0.86
Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol (2010) 0.85
DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus. Autoimmunity (2013) 0.84
Bifunctional, chemically patterned flat stamps for microcontact printing of polar inks. Langmuir (2008) 0.83
Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus. Arthritis Rheum (2013) 0.83
Endothelial nitric oxide synthase reduces crescentic and necrotic glomerular lesions, reactive oxygen production, and MCP1 production in murine lupus nephritis. PLoS One (2013) 0.82
Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J Immunol (2010) 0.82
Self-assembled monolayers of subphthalocyanines on gold substrates. Org Lett (2010) 0.82
Metabolic regulation of organelle homeostasis in lupus T cells. Clin Immunol (2012) 0.81
The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin Immunol (2006) 0.81
Identification of mitochondrial genome concatemers in AIDS-associated lymphomas and lymphoid cell lines. Leuk Res (2009) 0.81
Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase. Biochem J (2004) 0.80
The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity. Br J Clin Pharmacol (2006) 0.80
Lymphoedema: a paradoxical effect of tumour necrosis factor inhibitors - case report and review of literature. BMJ Case Rep (2009) 0.77
Differential regulation of hydrogen peroxide and Fas-dependent apoptosis pathways by dehydroascorbate, the oxidized form of vitamin C. Antioxid Redox Signal (2002) 0.77
Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity (2013) 0.76
The role of endocytic recycling in autoimmunity. Methods Mol Biol (2012) 0.76
Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE. Clin Immunol (2011) 0.75
Overview of signal processing by the immune system in systemic lupus erythematosus. Autoimmun Rev (2008) 0.75
Phase transfer of CdS nanocrystals mediated by heptamine β-cyclodextrin. Langmuir (2012) 0.75
Evaluation of autoimmunity to transaldolase in multiple sclerosis. Methods Mol Med (2004) 0.75
Computational methods for functional site identification suggest a substrate access channel in transaldolase. Genome Inform (2006) 0.75
Palpable purpura, polyarthritis and abdominal pain. Med J Aust (2004) 0.75
Surface modification of elastomeric stamps for microcontact printing of polar inks. Langmuir (2007) 0.75